MOVING SICKLE CELL

RESEARCH FORWARD.

The Sickle Cell Community says…

Sickle Cell Research Testimonials

Making an Informed Decision As a Family

4 mins WATCH NOW

Jewel is a teenager living with sickle cell disease. She and her mother, Paula make informed decision about participating in clinical studies.

My Contribution to Clinical Studies

3 mins WATCH NOW

Ada Gonzalez lives with sickle cell disease and enrolled in a clinical study decades ago that she benefits from today.

Andre Video

3 mins WATCH NOW

Jewel is a teenager living with sickle cell disease. She and her mother, Paula make informed decision about participating in clinical studies.

Updates

Oxbryta Increased Hemoglobin, Reduced Hemolysis in Adults and Adolescents

13 Apr 2021

Treatment with oral Oxbryta (voxelotor) leads to rapid and sustained rises in hemoglobin levels, reduces red blood cell destruction (hemolysis), and improves overall health in adolescents and adults with sickle cell disease (SCD), according to full, nearly 1.5-year data from the Phase 3 HOPE clinical trial.

FT-4202 at Higher Dose Safe and Helpful to Patients in Phase 1 Trial

08 Apr 2021

A higher 600 mg daily dose of FT-4202, a potential disease-modifying oral treatment for sickle cell disease (SCD), was well-tolerated and safe, and improved several measures of red blood cell health after 14 days of treatment, according to recent data from an ongoing Phase 1 trial.

GBT Granted Rights to SCD Small Molecule Programs in Deal With Sanofi

06 Apr 2021

Global Blood Therapeutics (GBT) has been granted exclusive global rights to two small-molecule research programs for sickle cell disease (SCD) as part of a newly announced agreement between GBT and Sanofi.

Join our newsletter

We send occasional updates that feature new trials, and other great tips. We will not spam you.

JOIN NOW
Have a question?
GET IN TOUCH WITH US.